Posted by ABMN Staff on Apr 24th, 2024
Wedbush reaffirmed their outperform rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $12.00 target price on the stock.
Several other...
More of this article »